Kimberly Lenz, PharmD, MBA
Articles
July 13th 2022
Cost-Benefit Analysis of Sacubitril/Valsartan in a Medicaid Population
Alan Gabot, PharmD Pavel Lavitas, PharmD, BCPS Rachel Bacon, PharmD, MPH Thomas C. Pomfret, PharmD, MPH, BCPS Mckenzie Taylor, PharmD, MS Andrew Coelho, PharmD Bonnie C. Greenwood, PharmD, BCPS Caroline J. Alper, MD Karen M. Clements, ScD Kimberly Lenz, PharmD, MBA
The cost avoidance of heart failure–related hospitalizations and emergency department visits may outweigh the additional drug cost in Medicaid members adherent to sacubitril/valsartan.
Latest Updated Articles
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: November 1st 2024 | Updated: November 21st 2024
Table Multiple Myeloma Trials November 2024
